Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes

Markus Weiller , Timo Weilandl , Georg Dünstl , Ulrike Sack , Gerald Künstle , Albrecht Wendel

Histone deacetylases (HD) represent a novel target in cancer treatment, in particular of scattered small tumours such as the hepatocellular carcinoma (HCC). However, only few studies address the toxicological impact of HD Inhibitors (HDIs) on malignantly transformed cells versus primary hepatocytes. We examined whether and how different classes of HDIs sensitise the human HCC cell line HepG2, primary healthy murine and human liver cells towards the death receptor agonists TNFα and CD95L.

Mots clés: ActD; CBHA; HDAC; HDI; M344; VPA; TNF; TRAIL; CD95L; cFLIP; XIAP; Hepatocellular carcinoma; Adverse side effect; Primary hepatocytes

Domaines: Toxicologie

Markus Weiller, Timo Weilandl, Georg Dünstl, Ulrike Sack, Gerald Künstle, et al.. Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes. Experimental and Toxicologic Pathology, 2011, 63 (5), pp.511. ⟨10.1016/j.etp.2010.04.001⟩. ⟨hal-00696622⟩